Journal Article Observational Study Research Support, Non-U.S. Gov't Epublish 16 citations
PubMed: 34960725 DOI: 10.3390/v13122456
Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection.
Viruses 13(12)
Authors: Wolfgang Bauer, Marcus Weber, Eva Diehl-Wiesenecker, Noa Galtung, Monika Prpic, Rajan Somasundaram, Rudolf Tauber, Jochen M Schwenk, Patrick Micke, Kai Kappert
Affiliations
- Department of Emergency Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.
- Zuse Institute Berlin (ZIB), Takustraße 7, 14195 Berlin, Germany.
- Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
- Labor Berlin-Charité Vivantes GmbH, 13353 Berlin, Germany.
- Science for Life Laboratory, KTH-Royal Institute of Technology, Tomtebodavägen 23, 17165 Solna, Sweden.
- Department of Immunology, Genetics and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 75185 Uppsala, Sweden.
Abstract
BACKGROUND
We evaluated how plasma proteomic signatures in patients with suspected COVID-19 can unravel the pathophysiology, and determine kinetics and clinical outcome of the infection.
METHODS
Plasma samples from patients presenting to the emergency department (ED) with symptoms of COVID-19 were stratified into: (1) patients with suspected COVID-19 that was not confirmed ( = 44); (2) non-hospitalized patients with confirmed COVID-19 ( = 44); (3) hospitalized patients with confirmed COVID-19 ( = 53) with variable outcome; and (4) patients presenting to the ED with minor diseases unrelated to SARS-CoV-2 infection ( = 20). Besides standard of care diagnostics, 177 circulating proteins related to inflammation and cardiovascular disease were analyzed using proximity extension assay (PEA, Olink) technology.
RESULTS
Comparative proteome analysis revealed 14 distinct proteins as highly associated with SARS-CoV-2 infection and 12 proteins with subsequent hospitalization ( < 0.001). ADM, IL-6, MCP-3, TRAIL-R2, and PD-L1 were each predictive for death (AUROC curve 0.80-0.87). The consistent increase of these markers, from hospital admission to intensive care and fatality, supported the concept that these proteins are of major clinical relevance.
CONCLUSIONS
We identified distinct plasma proteins linked to the presence and course of COVID-19. These plasma proteomic findings may translate to a protein fingerprint, helping to assist clinical management decisions.
MeSH
Infections, Plasma, Virology, Emergency Medicine, Proteomics, Sars Virus, Proteome, Covid-19, Sars-Cov-2
Cited by
- Mapping the Serum Proteome of COVID-19 Patients; Guidance for Severity Assessment. Biomedicines, 2022
- Proteomic insights into SARS-CoV-2 infection mechanisms, diagnosis, therapies and prognostic monitoring methods. Front Immunol, 2022
- Combining Deep Phenotyping of Serum Proteomics and Clinical Data via Machine Learning for COVID-19 Biomarker Discovery. Int J Mol Sci, 2022
- Development of a proteomic signature associated with severe disease for patients with COVID-19 using data from 5 multicenter, randomized, controlled, and prospective studies. Sci Rep, 2023
- The Circulating Proteome─Technological Developments, Current Challenges, and Future Trends. J Proteome Res, 2024
- Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions. PLoS One, 2025
- Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients. Cell Rep Med, 2022
- Coronavirus disease 2019-related myocardial injury is associated with immune dysregulation in symptomatic patients with cardiac magnetic resonance imaging abnormalities. Cardiovasc Res, 2024
- COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19. Int J Mol Sci, 2022